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The use of antisense 2′-deoxyoligonucleotides as
agents for specific downregulation of gene expression
is now well established (1). Most commonly, the
oligonucleotides base-pair with an mRNA target and
mediate its destruction by RNase H, an enzyme that
destroys the RNA in a DNA/RNA duplex. Numerous
clinical trials evaluating the use of downregulating
antisense oligonucleotides for the treatment of can-
cer and other diseases are now underway (2). The
oligonucleotide drug Vitravene, the first of such drugs
to be approved, is used to treat cytomegalovirus retini-
tis. More recently, antisense compounds are being
developed for manipulation of alternative splicing
patterns. In this way, the ratio of different splice vari-
ants can be altered, and the function of a gene
changed. Considering that there are approximately
30,000 human genes and that up to 60% are alterna-
tively spliced, this new antisense approach may have
far-reaching implications in the treatment of a variety
of diseases. Oligonucleotides can be used to silence
mutations that cause aberrant splicing, thus restoring
correct splicing and function of the defective gene.
This is important since close to 50% of genetic disor-
ders are caused by mutations that cause defects in pre-
mRNA splicing. Thus, targeting splicing with anti-
sense oligonucleotides significantly extends the clinical
potential of these compounds.
The requirements for oligonucleotides that shift
splicing are different from those for oligonucleotides
used to achieve downregulation. Specifically, they
must not activate RNase H, which would destroy the
pre-mRNA target before it could be spliced. They must
also be able to effectively compete with splicing factors
for access to target pre-mRNAs that reside within the
nuclei of cells. Several types of modified synthetic
oligonucleotides fit these criteria. For example, oligo-
nucleotides with modifications to the 2′ position, such
as 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE) and 2′-
O-aminopropyl, are RNase H inactive and generally
have higher nuclease resistance and affinity for target
sequences than their 2′-deoxy counterparts. Oligonu-
cleotides with backbones based on morpholino, pep-
tide nucleic acid (PNA), phosphoramidate and methyl-
phosphonate derivatives of nucleotides have similar
characteristics (2). Modifications to the bases, which
increase the affinity of oligonucleotides for their tar-
get, may facilitate favorable antisense activity in the
context of splicing (2). The above modifications rep-
resent the second or third generation of compounds
superior to the initially extensively studied phospho-
rothioate oligodeoxynucleotides, which frequently
exhibited nonspecific, non-antisense effects (1).
Correction of splicing by antisense
oligonucleotides
β-Globin. β-Thalassemia is a serious genetic blood dis-
order (3) in which production of β-globin, a subunit
of hemoglobin, is partially or entirely ablated by
mutations in the β-globin gene. The defect decreases
the oxygen-carrying capacity of red blood cells and
causes compensatory expansion of the bone marrow
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and, if untreated, fatal iron overload. Mutations that
cause splicing defects are common among tha-
lassemic patients. For example, mutations at position
654, 705, or 745 of intron 2 (IVS2) of human β-globin
pre-mRNA lead to creation of an aberrant 5′ splice site
and activation of a cryptic 3′ splice site within the
intron (Figure 1a). The result is the inclusion of part
of IVS2 (creating an in-frame stop codon) into the
spliced mRNA. As a potential therapeutic, RNase
H–inactive antisense oligonucleotides targeted to the
aberrant splice site block its use by the spliceosome,
restoring the use of the proper splice sites and thus
β-globin expression (Figure 1a).
Ex vivo correction of β-globin pre-mRNA was
accomplished in human erythroid progenitor cells (4).
Correction of splicing and upregulation of the β-glo-
bin protein were seen at concentrations of up to 45
µM morpholino oligomer delivered by temporary
mechanical disruption of the cells. Despite high
doses, sequence specificity was maintained and treat-
ment appeared generally nontoxic. Recent results show
that prolonged free uptake of morpholino oligonu-
cleotides also effectively corrects splicing in these cells
(5). Intracellular localization studies confirmed that
the antisense oligonucleotides must have entered the
nucleus in order to effectively modulate splicing.
Another β-globin mutation, βE, was also successfully
targeted using this approach (6). In an alternative and
potentially longer-term strategy, the antisense
sequences were incorporated into lentiviral expression
vectors and used to successfully treat human erythro-
poietic progenitor cells ex vivo (7).
Cystic fibrosis transmembrane conductance regulator. A
mutation (3849 + 10 kb C to T) in intron 19 of the cys-
tic fibrosis transmembrane conductance regulator
(CFTR) gene also creates an aberrant 5′ splice site and
activates a cryptic 3′ splice site (see Figure 1a). This
splicing defect accounts for roughly 2% of all cystic
fibrosis cases but is more frequent in the Ashkenazi
Jewish population. Treatment of cell lines expressing
this form of CFTR with antisense 2′-O-methyl
oligonucleotides targeted to either the 5′ or 3′ aber-
rant splice sites leads to dose-dependent increases in
CFTR protein expression (8). Interestingly, delivery of
both oligonucleotides simultaneously had an additive
effect, a result not seen with β-globin (R. Kole, unpub-
lished observations). Other splicing defect mutations
also occur in CFTR (9), representing additional poten-
tial targets for the antisense approach.
Dystrophin. Mutations that create stop codons in the
dystrophin gene are the main cause of Duchenne
muscular dystrophy (DMD). In contrast, a milder
form of the disease, Becker muscular dystrophy,
results from in-frame deletions. It was hypothesized
that oligonucleotides could be used to cause skipping
of the exon containing the stop codon, restoring the
reading frame and thus partially ameliorating the
DMD disease state (Figure 1b). Cells derived from the
mdx mouse model of DMD (containing the stop
codon in dystrophin exon 23) were treated with 2′-O-
methyl oligonucleotides targeted to the 5′ splice site
of the exon. This treatment caused exclusion of exon
23 from the spliced mdx message, thus reducing its
length by 213 nucleotides and eliminating the pre-
mature stop codon (10).
More recent work showed that formulations of the
same oligonucleotides injected directly into the mdx
mouse muscle modified splicing, restored the dys-
trophin reading frame (11), and increased the strength
of the injected muscle (12). Other studies have found
that targeting a splicing enhancer in another region
of the gene can also produce an exon-skipping effect
in cultured myotubes from DMD patients, and that a
skipping rate of only 15% was sufficient to restore
properly localized dystrophin to 75% of normal levels
in most cells (12, 13). The antisense oligonucleotide–
driven shift in splicing may be particularly attractive
as a treatment for DMD, since the dystrophin gene is
very large (2,400 kb) and therefore difficult to deliver
by current gene therapy protocols.
Tau. The tau gene codes for six splice variants of a neu-
ron-specific microtubule-associated protein. In human
neurons, exon 10 is normally skipped, because a hairpin
structure in the pre-mRNA sequesters its 5′ splice site.
Point mutations that disrupt the hairpin lead to inclu-
sion of exon 10 into the mRNA, causing a disorder man-
ifested by frontotemporal dementia and parkinsonism
linked to chromosome 17 (known as FTDP-17), with
Figure 1
Modification of splicing by antisense oligonucleotides. Aberrant splicing in thalassemic β-globin pre-mRNA or in certain splice mutants
in CFTR is prevented, and correct splicing is restored, by oligonucleotides (dark red bars) that block aberrant 5′ or 3′ cryptic splice
sites (a). Similarly, oligonucleotides induce skipping of a normal exon (gray) (b) or force selection of an alternative 5′ splice site (c) by
antisense oligonucleotides targeted to appropriate splice sites.
symptoms similar to those of Alzheimer disease. Two
rat cell lines, which express tau with exon 10, were used
as models for this splicing defect. Kalbfuss et al. deliv-
ered 2′-O-methyl oligonucleotide antisense to the dam-
aged hairpin structure to these cells in the hopes of
restoring the skipping of exon 10 (14). This treatment
resulted in a dose-dependent increase in the proportion
of tau that was devoid of exon 10 (Figure 1b). Correction
of splicing was very sensitive, with an EC50 of approxi-
mately 1.5 nM (effective concentration of the oligonu-
cleotide shifting splicing by 50%) when oligonucleotides
were delivered by electroporation. The treatment also
caused alterations in cell morphology as a result of
cytoskeletal-structure rearrangement, a therapeutically
favorable outcome.
Modification of alternative splicing 
by antisense oligonucleotides
In the above examples, gene function rendered defec-
tive by the splicing mutations was restored by anti-
sense oligonucleotides. Examples below demonstrate
modification of natural alternative splicing or induc-
tion of aberrant splicing that promises clinically rele-
vant outcomes.
Bcl-x. Bcl-x codes for two splice variants with opposing
functions that are derived by the use of two alternative
5′ splice sites. The long form, bcl-xL, has antiapoptotic
properties, while the short form, bcl-xS, has proapop-
totic properties. Both forms are required for the normal
cellular function; however, bcl-xL is over-represented in
a number of cancers, including prostate cancer (15).
Therefore, blocking the xL (proximal) 5′ splice site
should increase the ratio of bcl-xS to bcl-xL and thereby
simultaneously increase proapoptotic signals, decrease
antiapoptotic signals, and inhibit the growth or cause
the death of the cancer cells (Figure 1c).
Taylor et al. targeted the sequence adjacent to the
xL splice site with 2′-O-MOE phosphorothioate
oligonucleotide delivered by cationic lipids to A549
lung carcinoma cells (16). A dose-dependent and
sequence-specific increase in bcl-xS expression was
seen, with optimal shifting occurring at 24 hours
and 100–200 nM oligonucleotide. The newly syn-
thesized bcl-xS transcripts were successfully trans-
lated into protein. The resulting proapoptotic sig-
nal did not cause cell death but sensitized the A549
cells to apoptosis by cis-platinum. Interestingly,
Mercatante et al. demonstrated that an antisense 2′-
O-methyl oligonucleotide targeted to the xL splice
site alone induced apoptosis in PC3 prostate cancer
cells (17, 18). Here, maximal shifting of splicing
occurred with 80 nM oligonucleotide approximate-
ly 16–24 hours after delivery by cationic lipid trans-
fection. Increases in bcl-xS protein translation
peaked at 24–36 hours after treatment, suggesting
that the antisense effects are relatively long lasting.
Additional experiments showed that shifting of the
balance between bcl-xS and bcl-xL induces apopto-
sis in PC3 cells more effectively than does downregu-
lation of bcl-xL. Recent work indicates that the level of
expression of bcl-x gene is an important determinant of
cell sensitivity to bcl-x oligonucleotide treatment (18).
IL-5 receptor. A membrane-bound or a soluble form
of the IL-5 receptor (IL-5R) is generated by alternative
splicing and respective inclusion or exclusion of exon
9, which codes for the transmembrane domain of the
protein (19). The latter form may represent a decoy
receptor with no physiological function other than to
prevent signaling by IL-5. Therefore, preventing the
inclusion of exon 9 should not only decrease the num-
ber of functional IL-5Rs but also lead to a further
decrease in the available concentration of the agonist,
IL-5. This approach may have therapeutic effects on
diseases of inflammation, such as asthma. Antisense
2′-O-MOE oligonucleotides targeted to regions span-
ning exon 9 were delivered to B cell lymphoma cells by
electroporation (20). As expected, an increase in the
soluble IL-5R with a concomitant decrease in the
insoluble form was observed (see Figure 1b), suggest-
ing that the alternative splicing pathway of IL-5R was
manipulated. This notion was confirmed by treat-
ment of cells with an RNase H–competent oligonu-
cleotide targeted to the same region. This time, both
forms of the receptor were downregulated. Consider-
ing that the mRNA coding for the soluble form does
not contain the target sequence, the result strongly
suggests that the nuclear pre-mRNA was the primary
target of RNase H–mediated destruction (see “Evalu-
ation of next-generation antisense oligonucleotides”).
C-myc. C-myc is a powerful oncogene that is overex-
pressed or mutated in several types of cancer. Applica-
tion of antisense oligonucleotides for downregulation
of c-myc by a 28-mer morpholino oligomer directed
toward the AUG codon was unexpectedly shown to
cause aberrant splicing (21). It was found that, in addi-
tion to AUG, the oligonucleotide blocked the intron/
exon junction of exon 2, activating a cryptic 3′ splice
site further upstream within the exon. Thus, the
region of exon 2 containing the start codon was omit-
ted from the spliced message, leading to translation
initiation from a downstream AUG and generating a
truncated c-myc protein. This protein was detectable
with a c-myc antibody and did not appear when cells
were treated by random or sense control oligomers.
Clinically relevant potential targets for 
antisense oligonucleotides that shift splicing
Following the sequencing of the human genome, the
discrepancy between the number of genes and the
number of gene products suggests that a large num-
ber of the latter are generated by alternative splicing.
Thus, manipulation of alternative splicing may have
widespread applications. Discussed below are several
examples of potential targets for this approach.
Human insulin receptor. The gene encoding the
human insulin receptor (HIR) is expressed as two
different tissue-specific splice variants, HIR-A and
HIR-B, that exclude or include exon 11, respectively.
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It has been reported that HIR-A binds insulin with
higher affinity than does HIR-B but has lower sig-
naling capacity than the latter. Although the con-
clusions are somewhat conflicting (22), it appears
that the levels of inclusion of exon 11 in tissues may
contribute to type 2 diabetes. Manipulation of the
ratio between the splice variants may better elucidate
their functions and possibly result in therapeutic
applications of oligonucleotides. It appears that
there are exonic and intronic regions in the HIR pre-
mRNA that either negatively or positively influence
exon 11 splicing (23). Blocking of these regions as
well as the splice sites flanking the exon by antisense
oligonucleotides should allow for control over which
variant is expressed.
GABAA γ2. The GABAA γ2 gene is alternatively spliced
to generate a short (γ2S) and a long (γ2L) form. It was
recently shown that the ratio of γ2S to γ2L is severely
reduced in the prefrontal cortex of schizophrenia
patients (24) and in animal models of alcoholism (25).
This suggests that reduction of the levels of the long
form, in addition to increases in the levels of the short
form, could be of clinical benefit (Figure 1b). The
alternatively spliced exon is only 24 bp, allowing for
complete targeting by an antisense oligonucleotide
that, theoretically, would promote skipping and
improve the ratio of γ2S to γ2L.
Fibronectin. Fibronectin is an ECM protein critical
for the maintenance of normal skin. Different forms
of fibronectin can arise by alternative splicing of
three domains, known as EDA, EDB, and IIICS. One
form, called EDA+ Fn, includes the EDA domain and
is thought to be involved in the development of pso-
riasis (26), an immune and hyperproliferation disor-
der of the skin. Specifically, an increased ratio of
EDA+ Fn to EDA– Fn was found to be expressed in the
epidermis of psoriasis patients but not in controls,
suggesting the occurrence of a clinically relevant
alternative splicing event. Thus, oligonucleotide-in-
duced skipping of the EDA exon may ameliorate the
disease (Figure 1b).
Polycystic kidney disease. Polycystic kidney disease
(PKD) is among the most common inherited disor-
ders, with three genes (PKD1, PKD2, and PKD3)
known to be involved in its pathogenesis (27). One
known point mutation in PKD2 activates a cryptic 5′
splice site within exon 14 that is exclusively utilized in
preference to the still potentially functional, authen-
tic site (28). Interestingly, the activated splice site is 24
bp upstream of the mutation. Antisense oligonu-
cleotides targeted to either the point mutation or the
aberrant 5′ splice site may be sufficient to restore cor-
rect splicing, thus restoring PKD2 gene function.
Hepatic lipase. Deficiency in hepatic lipase (HL) leads
to hypertriglyceridemia and premature cardiovascular
disease. A mutation in intron 1 of HL causes generation
of a new 3′ splice site, which leads to a prematurely trun-
cated aberrant transcript and loss of HL function (29).
Figure 2
Site of action of antisense oligonucleotide. (I) From the extracellular space, an oligonucleotide or oligonucleotide/cationic lipid complex
interacts with the cell surface, presumably through receptor-ligand binding. (II) The oligonucleotide then undergoes endocytosis and is
thus sequestered from the rest of the cytoplasm. Alternatively (III) an oligonucleotide conjugated to cell-penetrating peptide fragments
may enter the cell via a nonendocytotic mechanism. (IV) Escape from the endosome is facilitated by the cationic lipid. Oligonucleotides
that do not escape are degraded in the lysosome (dashed arrow). (V) Once free in the cytoplasm, the oligonucleotide can passively dif-
fuse into the nucleus, where (VI) hybridization to the pre-mRNA target can take place. (VII) Export from the nucleus is energy dependent
and involves interactions of the oligonucleotide with nuclear export factors, such as the nuclear pore complex. (VIII) The biologically active
oligonucleotide can then bind cytoplasmic mRNA. (IX) The oligonucleotide can also dissociate from the mRNA target and recycle.
The new splice site is completely dominant, with no
correctly spliced message observed in the patient. Anti-
sense oligonucleotides targeted to this defect should
restore proper splicing. Though this mutation is cur-
rently thought to be uncommon, targeting of this and
other defects in HL with antisense compounds could
have great clinical benefit, considering that pharmaco-
kinetic data show the liver to be a favorable target for
oligonucleotide therapy (30, 31).
Prostate-specific membrane antigen. Prostate-specific
membrane antigen (PSM) has a long and a short splic-
ing isoform (PSM and PSM′) generated by the use of
alternative 3′ splice sites in exon 3. The PSM/PSM′
ratio is about 150 times higher in prostate cancer rel-
ative to normal tissue and may constitute a marker for
the emergence and progression of the disease (32).
Although there is no direct evidence that the long,
PSM form causes cancer, recent reports suggest that
PSM may be a valuable therapeutic target (33, 34).
Thus it would be of interest to determine the biolog-
ical effects of oligonucleotide-induced exon skipping
and restoration of the correct PSM/PSM′ ratio in
prostate cancer tissue.
Evaluation of next-generation 
antisense oligonucleotides
Downregulation of gene expression by RNase H–com-
petent oligonucleotides targeted to the AUG codon or
other sequences in mRNA is a predominant method
of utilizing these compounds (1). Reports also indi-
cate that targeting the AUG start codon with RNase
H–inactive oligonucleotides could successfully inhib-
it gene expression (35). Thus it seemed evident that
the mRNA located in the cytoplasm had to be the
intracellular site of action of these compounds. How-
ever, closer evaluation of the data strongly suggests
that the nucleus is actually the predominant site of
action of antisense molecules (Figure 2). Early reports
on antisense delivery agents showed that the marked
increase in efficacy of antisense molecules correlated
with their increased nuclear accumulation (36–38).
Furthermore, in the successfully targeted genes listed
above, the alteration of splicing patterns had to have
resulted from the binding of the oligonucleotide to
the nuclear pre-mRNA. Thus, it is clear that a mecha-
nism for evaluating the sequence-specific efficacy of
novel antisense compounds must reflect the nuclear
antisense activity of the compound.
An assay for the nuclear activity of antisense
oligonucleotides was developed, based on the cor-
rectable aberrant splicing of IVS2-654 human β–glo-
bin intron 2. This intron was inserted into the coding
sequence for enhanced GFP (EGFP) and thus pre-
vented expression of EGFP both in stable HeLa cell
lines (39) and in a transgenic mouse that ubiquitous-
ly expressed the EGFP-654 construct (31). Upregula-
tion of EGFP was accomplished by antisense oligonu-
cleotides directed at the aberrant 5′ splice site at
position 654 in the intron. Increases in EGFP pro-
duction were proportional to antisense activity of a
given oligonucleotide. Using these systems, RNase
H–inactive antisense compounds with novel or estab-
lished chemistry can be compared in both the cellular
and the animal model, on a standard platform with a
standardized sequence. Therefore, the variability in
sequence and output associated with different assays
is eliminated. Initial studies using the assay found
that negatively charged 2′-O-MOE phosphorothioate
and positively charged PNA-4K oligomers (PNA with
four positively charged lysine residues at the carboxy
[3′] end) had superior activity in the transgenic mouse
compared with uncharged oligomers such as mor-
pholino and PNA-1K (with one lysine). In cell culture,
free uptake of these oligomers was dependent on a
lack of negative charge or the presence of a positive
charge. These results demonstrate an apparent inabil-
ity of cell culture to predict in vivo efficacy; however,
in both instances, the positively charged oligomers
(e.g., PNA-4K) were most active. More work is needed
to optimize antisense oligonucleotides for in vivo and
clinical application, and the transgenic EGFP-654
mouse provides a useful tool for these experiments.
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